Article
2025 Mid-Year Highlights In Canadian Life Sciences IP And Regulatory Law
This comprehensive update examines the most significant developments in Canadian life sciences intellectual property and regulatory law during the first half of 2025, covering landmark patent litigation, evolving regulatory frameworks, and major policy shifts affecting pharmaceutical market access. From Federal Court decisions on biosimilar patents to new PMPRB pricing guidelines and national pharmacare agreements, these developments are reshaping the landscape for innovators and generic manufacturers alike

Smart & Biggar






